TY - JOUR
T1 - Characterizing prostatic adenocarcinomas in men with a serum prostate specific antigen level of <4.0 ng/mL
AU - Sokoloff, M. H.
AU - Yang, X. J.
AU - Fumo, M.
AU - Mhoon, D.
AU - Brendler, C. B.
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2004/3
Y1 - 2004/3
N2 - OBJECTIVE: To characterize prostate cancer in men undergoing radical prostatectomy who have a prostate-specific antigen (PSA) level of <4.0 ng/mL, hypothesising that a low PSA is not caused by diminished tumour production of PSA, nor does it signify clinically insignificant disease. PATIENTS AND METHODS: Seventy-nine men (mean age 59.3 years, range 43-77) with a PSA level of <4. 0 ng/mL were identified from 702 who had a radical prostatectomy between 1994 and 2000. Demographic and clinical data were analysed; pathological specimens were evaluated by routine haematoxylin and eosin staining and immunohistochemistry with anti-PSA antibody, for both pathological staging and grading, and for the presence of PSA production. Tumours were classified as 'clinically insignificant' if the tumour volume was <0.5 ml and the Gleason score <7. RESULTS: The mean (SD, range) preoperative PSA level was 3.04 (0.85, 0.8-3.8) ng/mL. Indications for biopsy included an abnormal digital rectal examination (61%), a PSA velocity of >075 ng/mL/year (12%), a strong family history of prostate cancer (3%), obstructive urinary symptoms (2%), or no obvious indication (23%). Thirty-eight (48%) tumours were clinically insignificant. Of 41 clinically significant cancers, 13 had a final Gleason score of ≥7, 20 had extraprostatic extension and 11 had a tumour volume of ≥10 mL. Of the 79 prostate cancer specimens 78 stained strongly for PSA; the exception was a Gleason 9 tumour. With a mean (range) follow-up of 3.5 (0.18-6) years only one patient had a biochemical recurrence (PSA ≥0.1 ng/mL). CONCLUSIONS: Most prostate cancers in men with a PSA level of <4.0 ng/mL are clinically significant and PSA-producing. Many of these tumours are high-grade, high-volume and extraprostatic. We are currently exploring factors to explain why serum PSA is not elevated in these men, including tumour location, pattern of invasion and microvessel density.
AB - OBJECTIVE: To characterize prostate cancer in men undergoing radical prostatectomy who have a prostate-specific antigen (PSA) level of <4.0 ng/mL, hypothesising that a low PSA is not caused by diminished tumour production of PSA, nor does it signify clinically insignificant disease. PATIENTS AND METHODS: Seventy-nine men (mean age 59.3 years, range 43-77) with a PSA level of <4. 0 ng/mL were identified from 702 who had a radical prostatectomy between 1994 and 2000. Demographic and clinical data were analysed; pathological specimens were evaluated by routine haematoxylin and eosin staining and immunohistochemistry with anti-PSA antibody, for both pathological staging and grading, and for the presence of PSA production. Tumours were classified as 'clinically insignificant' if the tumour volume was <0.5 ml and the Gleason score <7. RESULTS: The mean (SD, range) preoperative PSA level was 3.04 (0.85, 0.8-3.8) ng/mL. Indications for biopsy included an abnormal digital rectal examination (61%), a PSA velocity of >075 ng/mL/year (12%), a strong family history of prostate cancer (3%), obstructive urinary symptoms (2%), or no obvious indication (23%). Thirty-eight (48%) tumours were clinically insignificant. Of 41 clinically significant cancers, 13 had a final Gleason score of ≥7, 20 had extraprostatic extension and 11 had a tumour volume of ≥10 mL. Of the 79 prostate cancer specimens 78 stained strongly for PSA; the exception was a Gleason 9 tumour. With a mean (range) follow-up of 3.5 (0.18-6) years only one patient had a biochemical recurrence (PSA ≥0.1 ng/mL). CONCLUSIONS: Most prostate cancers in men with a PSA level of <4.0 ng/mL are clinically significant and PSA-producing. Many of these tumours are high-grade, high-volume and extraprostatic. We are currently exploring factors to explain why serum PSA is not elevated in these men, including tumour location, pattern of invasion and microvessel density.
KW - Clinically significant
KW - Immunohistochemistry
KW - PSA
KW - Prostate cancer
KW - Prostatectomy
UR - http://www.scopus.com/inward/record.url?scp=1642311092&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1642311092&partnerID=8YFLogxK
U2 - 10.1111/j.1464-410X.2003.04657.x
DO - 10.1111/j.1464-410X.2003.04657.x
M3 - Article
C2 - 15008717
AN - SCOPUS:1642311092
SN - 1464-4096
VL - 93
SP - 499
EP - 502
JO - BJU International
JF - BJU International
IS - 4
ER -